Having trouble viewing email? VIEW IN WEB BROWSER»
FDA Indication for MyoSure
FDA clears the Myosure® system for a new indication - the removal of retained products of conception.

Retained products of conception (RPOC) is non-viable pregnancy tissue that has not passed due to:
- Failed expectant management.
- Post treatment of miscarriage.
- Term delivery.
Traditional D&C is the most common treatment for RPOC,
but the data shows:
- Increased risk of perforation, infection and bleeding.1
- 19% incidence of adhesion formation after D&C.2
- Up to 32% incidence of adhesion formation after multiple D&C procedures.2

The MyoSure system is a solution for the removal of RPOC:
- Remove only the targeted tissue.
- Reduced risk of damage to healthy tissue.
- Direct visualization for confirmation of removal.




Offer your patients the best treatment option, while preserving their future fertility.  


Watch a video


Case study of the MyoSure system use for removal of retained products of conception


Learn more about the MyoSure system MyoSure.com



1. Sadan O, et al. Role of sonography in the diagnosis of retained products of conception. J Ultrasound Med 2004; 23:371-74. 2. Friedler S, Margaloioth EJ, Kafka I, Yaffe H. Incidence of post-abortion intra-uterine adhesions evaluated by hysteroscopy-a-prospective study. Hum Reprod. 1993;8:442-444

EMB-00627-001 Hologic and MyoSure are registered trademarks of Hologic, Inc., or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, write to womenshealth@hologic.com